Glaukos Co. (NYSE:GKOS – Get Rating) was the recipient of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 4,720,000 shares, an increase of 5.6% from the February 13th total of 4,470,000 shares. Based on an average daily volume of 398,600 shares, the short-interest ratio is presently 11.8 days. Currently, 10.3% of the company’s shares are short sold.
Glaukos Trading Down 1.9 %
Shares of GKOS traded down $0.96 during mid-day trading on Friday, hitting $48.45. The company’s stock had a trading volume of 158,909 shares, compared to its average volume of 418,182. The company’s 50-day moving average is $48.74 and its 200-day moving average is $49.57. Glaukos has a 52-week low of $33.33 and a 52-week high of $64.49. The company has a debt-to-equity ratio of 0.67, a current ratio of 6.13 and a quick ratio of 5.61.
Glaukos (NYSE:GKOS – Get Rating) last announced its quarterly earnings results on Wednesday, February 22nd. The medical instruments supplier reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.03. Glaukos had a negative net margin of 35.07% and a negative return on equity of 18.51%. The firm had revenue of $71.23 million during the quarter, compared to analysts’ expectations of $67.71 million. As a group, analysts expect that Glaukos will post -2.38 EPS for the current year.
Institutional Investors Weigh In On Glaukos
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. lifted their price target on shares of Glaukos from $42.00 to $48.00 and gave the stock a “neutral” rating in a research note on Thursday, February 23rd. StockNews.com initiated coverage on shares of Glaukos in a research note on Thursday. They set a “sell” rating for the company. Stephens lowered their price objective on shares of Glaukos from $69.00 to $68.00 and set an “overweight” rating for the company in a research report on Wednesday, December 28th. Needham & Company LLC lowered their price objective on shares of Glaukos from $58.00 to $57.00 and set a “buy” rating for the company in a research report on Thursday, February 23rd. Finally, Citigroup boosted their price objective on shares of Glaukos from $57.00 to $59.00 and gave the company a “buy” rating in a research report on Thursday, February 23rd. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $56.67.
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B.
- Get a free copy of the StockNews.com research report on Glaukos (GKOS)
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
- PacWest Bancorp May Escape a Credit Downgrade After this Happens
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.